Navigation Links
Haemacure Announces Preliminary Findings of its Plasma Discard,Analysis


MONTREAL, June 14, 2007 /PRNewswire-FirstCall/ Haemacure Corporation , a Montreal-based specialty biotherapeutics company, today announced the preliminary findings of the content analysis of one of its plasma discards.

Preliminary findings confirm the presence of a number of proteins and enzymes with applications in significant worldwide markets, including albumin, plasminogen, immunoglobulin and A1PI.

These findings take on a strategic significance for Haemacure as revenues eventually generated from the commercial exploitation of these proteins and enzymes will constitute a direct contribution to the bottom line. This is because the cost of the plasma will be fully borne by Haemacure's fibrin sealant and hemostatic agent once these products will be commercialized.

"We are very excited with the positive outcome of the content analysis of one of our plasma discards," said Joseph Galli, Chairman and Chief Executive Officer of Haemacure. "This is the first tangible result of our new biotherapeutics orientation that we announced at our recent meeting of shareholders. The identification of these proteins and enzymes indicates that our patented plasma protein extraction technology yields significant potential benefits superior to the traditional extraction technology. With these results in hand, and further to interest expressed by third parties in our plasma discard, we will drive towards implementing our business development strategy that encompasses partnerships with pharmaceutical and biotechnology companies." concluded Mr. Galli.

Haemacure plans on harvesting albumin from this discard and using it in the production of its fibrin sealant, representing annual cost savings estimated at more than US$500,000 at full production plant capacity. Some albumin extracted could also be available for commercialization.

According to the Marketing Research Bureau, the world pla sma-derived protein market is estimated to reach US$8.5 billion by 2010. The North American market was estimated at US$2.4 billion in 2006. Immunoglobulin is the biggest selling protein in North America, with sales estimated at US$1.4 billion in 2006 in the United States alone. Immunoglobulin is used to treat immunological, neurological and other disorders. Plasminogen, once converted into plasmin, is a clot buster and offers a natural alternative to synthesized solutions to address an unmet need of the market. A1PI is used by patients suffering from hereditary emphysema resulting from A1PI deficiency. A1PI deficiency affects between 60,000 to 100,000 people in the United States.

According to Cowen and Company, enzyme replacement therapies (ERTs) will reach US$3.1B in 2011. ERTs are the cornerstone of treatment of many orphan disorders, particularly the lysosomal storage diseases. Orphan diseases are comprised of number different conditions that each afflict only a small number of individuals, but together constitute one of the most lucrative therapeutic areas. The four leading lysosomal disorder products are intended to treat Gaucher's disease, Fabry's disease, Hurler's disease and Pompe's disease.

In 2006, estimated sales for these four leading lysosomal disorder products were US$1 billion, US$359 million, US$96 million and US$30 million respectively, nearly US$1.5 billion in total. Haemacure has identified in its plasma discard enzymes each treating one of these diseases. The enzymes are alpha-galactosidase, used to treat Fabry's disease, alpha-glucosidase, used to treat Pompe's disease, beta-glucosidase, used to treat Gaucher's disease, and alpha-iduronidase, used to treat Hurler's disease.

Haemacure has also identified three other enzymes, used to treat Hunter's disease, Morquio's disease and Shindler's disease. Products are also in development for these diseases.

As advised, these findings are preliminary and the full value of these proteins and enzymes cannot be realized without FDA approval. Haemacure will continue identification work on its plasma discard and seek partnerships with pharmaceutical and biotechnology companies that would fund the development and clinical activities required to bring these proteins and enzymes to market and with which it would share sales revenues.

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company focused on developing and commercializing premium human therapeutic proteins. Haemacure utilizes its proprietary plasma protein extraction technology to develop next generation products, including hemostats for surgical use. Haemacure's lead product candidate, Hemaseel(TM)HMN, an all-human fibrin sealant, is in late stage clinical development for biosurgical applications. The second product, an all-human thrombin, a component of fibrin sealant, also has applications as a stand-alone product in the expanding biosurgical market. Follow-on development will focus on biomaterial combinations and drug delivery in select therapeutic areas. Haemacure will develop partnerships to advance specialty proteins that it has recently identified in its plasma-derived intermediates to address the unmet medical needs of patients. Haemacure also operates offices in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol HAE on the TSX.

Forward-looking Statements

Certain of the statements contained in this news release are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure Corporation does business, stock market volatility, fluctuations in costs, and changes to the competit ive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Haemacure Corporation disclaims any intention or obligation to update these statements.

CONTACT: Joseph Galli, Chairman and CEO, Haemacure Corporation, (514)990-7074; Gilles Lemieux, Investor Relations, Haemacure Corporation, (514)282-3350 ext. 22, Cel: 514-968-1382

Ticker Symbol: (Toronto:HAE.)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:11/25/2015)... announced the issue of United States patent No. 9,192,509  entitled: " Methods ... the company,s AVACEN 100 dry heat therapy medical device and specific methods of use, referred to ... Photo - ... ... ...
(Date:11/25/2015)... , Nov. 25, 2015 USP ... hazardous drug preparations (e.g. pharmacists, pharmacy technicians, nurses, ... veterinary technicians). The chapter also covers all entities ... (e.g., pharmacies, hospitals, other healthcare institutions, patient treatment ... --> --> What ...
(Date:11/25/2015)... Nov. 25, 2015  Mindray Medical ... MR ), a leading developer, ... worldwide, today announced that it will ... of shareholders at the Company,s Hong Kong office ... Prince Edward West Road, Mongkok KL, Hong ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Privately ... has undertaken significant expansion of its current state of the art research, development ... PharmaTech’s strategy to increase its manufacturing capacity as well as to support its ...
(Date:11/25/2015)... ... November 25, 2015 , ... Many people know of the ... gain, cold hands, and dry skin. But many people who find their cholesterol levels ... regimen instead of their thyroid, especially if they don’t have any of the other ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... on providing comprehensive solutions involving adult stem cell therapies to patients with chronic ... the “Regenestem” name as a Registered Trademark (RTM). , Organizations are required to ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... prices in an early celebration of the early holiday shopping season. Starting Wednesday ... each (normally $33.95 ea). Black Friday promotional pricing is in addition to any ...
(Date:11/24/2015)... ... November 24, 2015 , ... Eric C. ... the many benefits of the revolutionary BIOLASE WaterLase iPlus 2.0™ system. This advanced ... traditionally used by a dentist in Gettysburg, PA . From routine visits ...
Breaking Medicine News(10 mins):